Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786095 | 1.00 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL2784873 | 1.00 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL31575064 | 1.00 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL2786002 | 0.97 | HRH3 (1.00) | HRH3KCNH2 | |
| Phosphoric Acid SCHEMBL3732391 | 0.94 | HRH3 (0.89) | HRH3KCNH2 | |
| Phosphoric Acid SCHEMBL116823 | 0.94 | HRH3 (0.89) | HRH3KCNH2 | |
| SCHEMBL2784327 | 0.92 | HRH3 (0.85) | HRH3KCNH2 | |
| SCHEMBL2784329 | 0.92 | HRH3 (0.85) | HRH3KCNH2 | |
| SCHEMBL2783820 | 0.92 | HRH3 (0.85) | HRH3KCNH2 | |
| SCHEMBL2784898 | 0.91 | HRH3 (1.00) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| CN-115803088-B | Cyclobenzaprine treatment of sexual dysfunction | 通尼克斯医药控股公司 | 2025-03-21 | — | — | CN | claimed |
| US-20240415789-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMA LIMITED (IE) | 2024-12-19 | — | — | US | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4412602-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | Tonix Pharmaceuticals Holding Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | claimed |
| EP-4294446-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | Agonex Biopharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230390215-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | AGONEX BIOPHARMACEUTICALS, INC. | 2023-12-07 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | claimed |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HANCOCK ARTHUR A (US) | 2005-05-26 | — | — | US | claimed |
| US-20040054185-A1 | Process for preparing amine-substituted benzofurans | COWART MARLON D (US) | 2004-03-18 | — | — | US | claimed |
| EP-1370546-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | claimed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | claimed |
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-12-05 | — | — | US | claimed |
| US-20020177589-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | claimed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002074758-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | HRH3 3911/4885KCNH2 4854/4885 |
| US-20020177589-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 948/4885 |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1106/4885 |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 948/4885 |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 919/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | HRH3 1008/4885KCNH2 3957/4885 |
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 948/4885 |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 919/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 946/4885 |
| US-20040054185-A1 | Process for preparing amine-substituted benzofurans | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.